Am J Respir Crit Care Med:高流量鼻导管治疗稳定期合并高碳酸血症COPD

2022-07-14 小文子 MedSci原创

研究评估了长期高流量鼻导管是否可以减少因慢性阻塞性肺疾病导致的慢性高碳酸血症呼吸衰竭患者的急性加重次数并改善其他生理参数。

高流量鼻导管对慢性阻塞性肺疾病引起的慢性高碳酸血症呼吸衰竭的长期影响仍不清楚。American Journal of Respiratory and Critical Care Medicine杂志近期发表了一篇文章,该研究评估了长期高流量鼻导管是否可以减少因慢性阻塞性肺疾病导致的慢性高碳酸血症呼吸衰竭患者的急性加重次数并改善其他生理参数。

研究招募了 104 名日间高碳酸血症(GOLD分期 2-4 期)参与者(年龄≥40 岁),患者接受长期氧疗(≥16小时/天,持续1个月以上),并随机分配至高流量鼻导管/长期氧疗组和长期氧疗组。主要终点是中度/重度急性加重率。研究比较了动脉血气值、外周血氧饱和度、肺功能、健康相关生活质量评分和 6 分钟步行试验相较于基线的变化。

高流量鼻插管显着降低了中/重度急性加重的发生率(未调整的平均计数 1.0 vs 2.5,组间调整后平均计数比值为2.85,95%CI,1.48–5.47),并延长了无中度/重度急性加重的持续时间。长期氧疗组首次发生中度/重度急性加重的中位时间为 25(14.1~47.4)周,高流量鼻导管/长期氧疗组没有发生急性加重。高流量鼻导管显着改善了健康相关生活质量评分、外周血氧饱和度和肺功能参数。没有发现安全问题。

结果表明,高流量鼻导管是治疗伴高碳酸血症的稳定期慢性阻塞性肺疾病并有加重病史患者的合理选择。

原文出处:

Kazuma Nagata , Takeo Horie, et al, Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Trial, Am J Respir Crit Care Med, 2022, doi: 10.1164/rccm.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1585987, encodeId=599c158598ece, content=<a href='/topic/show?id=30e110253124' target=_blank style='color:#2F92EE;'>#高碳酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102531, encryptionId=30e110253124, topicName=高碳酸血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aff417344311, createdName=lvygwyt2787, createdTime=Fri Jul 15 00:55:59 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611655, encodeId=4d5b1611655a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 15 00:55:59 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232393, encodeId=f1d91232393a8, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Thu Jul 14 10:35:41 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232392, encodeId=8b761232392c7, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Thu Jul 14 10:35:32 CST 2022, time=2022-07-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1585987, encodeId=599c158598ece, content=<a href='/topic/show?id=30e110253124' target=_blank style='color:#2F92EE;'>#高碳酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102531, encryptionId=30e110253124, topicName=高碳酸血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aff417344311, createdName=lvygwyt2787, createdTime=Fri Jul 15 00:55:59 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611655, encodeId=4d5b1611655a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 15 00:55:59 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232393, encodeId=f1d91232393a8, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Thu Jul 14 10:35:41 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232392, encodeId=8b761232392c7, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Thu Jul 14 10:35:32 CST 2022, time=2022-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1585987, encodeId=599c158598ece, content=<a href='/topic/show?id=30e110253124' target=_blank style='color:#2F92EE;'>#高碳酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102531, encryptionId=30e110253124, topicName=高碳酸血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aff417344311, createdName=lvygwyt2787, createdTime=Fri Jul 15 00:55:59 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611655, encodeId=4d5b1611655a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 15 00:55:59 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232393, encodeId=f1d91232393a8, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Thu Jul 14 10:35:41 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232392, encodeId=8b761232392c7, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Thu Jul 14 10:35:32 CST 2022, time=2022-07-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1585987, encodeId=599c158598ece, content=<a href='/topic/show?id=30e110253124' target=_blank style='color:#2F92EE;'>#高碳酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102531, encryptionId=30e110253124, topicName=高碳酸血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aff417344311, createdName=lvygwyt2787, createdTime=Fri Jul 15 00:55:59 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611655, encodeId=4d5b1611655a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 15 00:55:59 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232393, encodeId=f1d91232393a8, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Thu Jul 14 10:35:41 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232392, encodeId=8b761232392c7, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Thu Jul 14 10:35:32 CST 2022, time=2022-07-14, status=1, ipAttribution=)]
    2022-07-14 ms6000000960504356

    不错的文章

    0

相关资讯

Respir Res:我国慢阻肺严重程度分布与治疗现状

COPD患者普遍存在中重度气流受限、症状严重和病情恶化风险。维持疗法的处方并没有完全遵循指南建议。

一例一呼一吸与免疫力的“小纠纷”

现代研究普遍认为COPD是一种以炎症为中心、多种机制参与的疾病,有学者提出COPD是一种自身免疫性疾病。

NPJ Vaccines:疫苗株对慢性阻塞性肺疾病患者和健康老年人流感疫苗免疫后血清阳转率的影响

慢性阻塞性肺疾病(COPD)是一种常见的、严重的肺部疾病,由吸烟和暴露在空气污染物中引起。

Sci Total Environ:气候介导的空气污染与COPD严重程度相关

气候介导的空气污染增加了COPD患者FEV1和血氧饱和度降低以及肺气肿严重程度增加的风险。

Ann Intensive Care:高强度与低强度NPPV对AECOPD患者的生理影响

高强度NPPV在降低AECOPD患者的PaCO2、吸气费力,缓解呼吸困难,改善意识和NPPV耐受性方面是否比低强度NPPV更有效?

CHEST:慢阻肺单一吸入器与多重吸入器三联疗法,哪个更优?

开始SITT治疗的患者具有临床相关的持续性改善。